Skip to main content

Table 1 patient characteristics at diagnosis of brain metastases and treatments

From: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

Patient and tumor characteristics HER-2 negative patients HER-2 positive patients not treated with trastuzumab HER-2 positive patients treated with trastuzumab Whole population P value
  N = 78 N = 20 N = 32 N = 130  
  -60% -15.38% -24.62%   
Age at BM diagnosis (years)- median (range)      
   < 65 years 54(34-83) 53 (33- 75) 47(26-67) 52(26-83) 0.0178
   ≥ 65 years 59/77 (76.62) 15/20 (75) 31/32 (96.88) 105/129 (81.4)  
  18/77 (23.38) 5/20 (25) 1/32 (3.12) 24/129 (18.6)  
Karnofsky performance status      
   < 70 32/76 (42.11) 10/20 (50) 6/31 (19.35) 48/127 (37.8) 0.0418
   ≥ 70 44/76 (57.89) 10/20 (50) 25/31 (80.65) 79/127 (62.2)  
RTOG RPA class 0 0 0 0 0.0391
   I 43/75 (57.33) 10/20 (50) 25/31 (80.65) 78/126 (61.9)  
   II 32/75 (42.67) 10/20 (50) 6/31 (19.35) 48/126 (38.1)  
   III      
Histology of primary BC      
   Ductal 70/76 (92.11) 19/20 (95) 30/32 (93.75) 119/128 (92.97) 0.5172** (ns)
   Lobular 2/76 (2.63) 0 2/32 (6.25) 4/128 (3.12)  
   Other 4/76 (5.26) 1/20 (5) 0 5/128 (3.91)  
Histologic grade      
   SBR I 2/70 (2.86) 1/17 (5.88) 1/31 (3.23) 4/118 (3.39) 0.063** (ns)
   SBR II 27/70 (38.57) 1/17 (5.88) 11/31 (35.48) 39/118 (33.05)  
   SBRIII 41/70 (58.57) 15/17 (88.24) 19/31 (61.29) 75/118 (63.56)  
Tumor HR status      
   Positive 48/76 (63.16) 9/19 (47.37) 17/32 (53.12) 72/127 (56.69) 0.1996 (ns)
   Negative 28/76 (36.84) 10/19 (52.63) 15/32 (46.88) 55/127 (43.31)  
Number of BM      
   Single 6/78 (7.69) 0 0 6/130 (4.62) 0.1339** (ns)
   Multiple 72/78 (92.31) 20/20 (100) 32/32 (100) 124/130 (95.38) 0.1778 **(ns)
   Meningitis 17/77 (22.08) 1/20 (5) 4/31 (12.9) 22/128 (17.19)  
   Yes 60/77 (77.92) 19/20 (95) 27/31 (87.1) 106/128 (82.81)  
   No      
Number of other metastatic sites      
   0 (BM alone) 6/78 (7.69) 1/20 (5) 0 7/130 (5.38) 0.2971** (ns)
   1 19/78 (24.36) 3/20 (15) 9/32 (28.12) 31/130 (23.85)  
   2 20/78 (25.64) 7/20 (35) 14/32 (43.75) 41/130 (31.54)  
   > 2 33/78 (42.31) 9/20 (45) 9/32 (28.12) 51/130 (39.23)  
Concomitant and other metastases      
   Liver 35/78 (44.87) 12/20 (60) 23/32 (71.88) 70/130 (53.85) 0.0299
   Lung 36/78 (46.15) 11/20 (55) 14/32 (43.75) 61/130 (46.92) 0.7147 (ns)
   Bone 51/78 (65.38) 10/20 (50) 18/32 (56.25) 79/130 (60.77) 0.3783 (ns)
Previous chemotherapy 55/78 (70.51) 18/20 (90) 32/32 (100) 105/130 (80.77) 0.0002**
   Yes 23/78 (29.49) 2/20 (10) 0 25/130 (19.23)  
   No      
Previous taxane-based chemotherapy 36/78 (46.15) 11/20 (55) 25/31 (80.65) 72/129 (55.81) 0.0047
   Yes 42/78 (53.85) 9/20 (45) 6/31 (19.35) 57/129 (44.19)  
   No      
Lactate Deshydrogenase (LDH) 35/61 (57.38) 9/14 (64.29) 13/19 (68.42) 57/94 (60.64) 0.6597 (ns)
≤ 500 UI/L 26/61 (42.62) 5/14 (35.71) 6/19 (31.58) 37/94 (39.36)  
500 UI/L 127-2088 120-3469 158-2199 120-3469  
range      
Lymphocyte count 25/70 (35.71) 9/20 (45) 3/20 (15) 37/110 (33.64) 0.1106 (ns)
≤ 0.7 G/L 45/70 (64.29) 11/20 (55) 17/20 (85) 73/110 (66.36)  
> 0.7 G/L 61-2285 40-1814 63-2050 40-2285  
range      
Vital Status 16/78 (20.51) 2/20 (10) 14/32 (43.75) 18/32 (56.25) 32/130 (24.62) 0.0138**
alive 62/78 (79.49) 18/20 (90)   98/130 (75.38)  
dead      
  1. Abbreviations: BM = brain metastases; BC = breast cancer; SBR = Scarff-Bloom-Richardson grade; HR = hormone receptor; RTOG = Radiation
  2. ** Fisher's exact test
  3. Values are numbers (percentage), unless otherwise stated.